WG
SRPT icon

Winton Group’s Sarepta Therapeutics SRPT Stock Holding History

Winton Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-51,209
Closed -$1.11M – 1470
2026
Q1 		$1.11M Buy
51,209
+39,909
+353% +$772K 0.04% 513
2025
Q4 		$243K Buy
+11,300
New +$238K 0.01% 788
2025
Q2 		– Sell
-12,793
Closed -$816K – 992
2025
Q1 		$816K Buy
12,793
+7,213
+129% +$759K 0.05% 461
2024
Q4 		$678K Buy
+5,580
New +$684K 0.05% 418
2024
Q3 		– Sell
-2,688
Closed -$425K – 761
2024
Q2 		$425K Buy
+2,688
New +$345K 0.03% 444
2023
Q3 		– Sell
-2,823
Closed -$323K – 919
2023
Q2 		$323K Sell
2,823
-3,342
-54% -$431K 0.03% 502
2023
Q1 		$850K Sell
6,165
-6,732
-52% -$873K 0.05% 499
2022
Q4 		$1.67M Buy
+12,897
New +$1.49M 0.11% 246
2022
Q1 		– Sell
-10,430
Closed -$939K – 1134
2021
Q4 		$939K Buy
+10,430
New +$892K 0.06% 480
2021
Q2 		– Sell
-4,664
Closed -$348K – 1510
2021
Q1 		$348K Sell
4,664
-847
-15% -$78.2K 0.02% 1077
2020
Q4 		$940K Sell
5,511
-27,895
-84% -$4.13M 0.07% 438
2020
Q3 		$4.69M Sell
33,406
-7,825
-19% -$1.19M 0.15% 137
2020
Q2 		$6.61M Buy
41,231
+4,909
+14% +$668K 0.17% 128
2020
Q1 		$3.55M Buy
36,322
+17,036
+88% +$1.95M 0.09% 380
2019
Q4 		$2.49M Buy
19,286
+9,162
+90% +$925K 0.03% 719
2019
Q3 		$763K Buy
10,124
+5,552
+121% +$656K 0.01% 946
2019
Q2 		$695K Sell
4,572
-2,999
-40% -$364K 0.01% 539
2019
Q1 		$902K Sell
7,571
-2,802
-27% -$360K 0.02% 367
2018
Q4 		$1.13M Buy
10,373
+4,578
+79% +$573K 0.02% 331
2018
Q3 		$936K Sell
5,795
-431
-7% -$58.9K 0.02% 417
2018
Q2 		$823K Sell
6,226
-4,765
-43% -$449K 0.02% 490
2018
Q1 		$814K Buy
+10,991
New +$733K 0.02% 586

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Winton Group's SRPT Position: Q2 2026 in Review

Winton Group sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 51,209 shares — an estimated $1.11M sold.

Winton Group first reported a position in SRPT in Q1 2018 and held it in 22 quarters. The position peaked at $6.61M in Q2 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Winton Group reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Winton Group sold 51,209 Sarepta Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Winton Group first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 22 quarters.
  • Winton Group's Sarepta Therapeutics position peaked at $6.61M in Q2 2020.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.